JP2001524826A - 全身性紅斑性狼瘡を治療するためのペプチド - Google Patents
全身性紅斑性狼瘡を治療するためのペプチドInfo
- Publication number
- JP2001524826A JP2001524826A JP54532898A JP54532898A JP2001524826A JP 2001524826 A JP2001524826 A JP 2001524826A JP 54532898 A JP54532898 A JP 54532898A JP 54532898 A JP54532898 A JP 54532898A JP 2001524826 A JP2001524826 A JP 2001524826A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- laminin
- antibody
- analogs
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 87
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 31
- 201000000596 systemic lupus erythematosus Diseases 0.000 title claims abstract description 31
- 102000007547 Laminin Human genes 0.000 claims abstract description 30
- 108010085895 Laminin Proteins 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 26
- YIYCUMYWGOOSNU-FMZZOXHWSA-N 2-[[(2s)-1-[(2s,3s)-2-[[(2s,3r)-2-[[2-[[(2s)-2-amino-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]acetic acid Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O YIYCUMYWGOOSNU-FMZZOXHWSA-N 0.000 claims abstract description 17
- 239000000126 substance Substances 0.000 claims abstract description 3
- 230000027455 binding Effects 0.000 claims description 35
- 230000003172 anti-dna Effects 0.000 claims description 22
- 210000002700 urine Anatomy 0.000 claims description 19
- 238000002965 ELISA Methods 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 7
- 150000007523 nucleic acids Chemical group 0.000 claims description 7
- 238000002835 absorbance Methods 0.000 claims description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 5
- 238000012544 monitoring process Methods 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000007790 solid phase Substances 0.000 claims description 3
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000003556 assay Methods 0.000 abstract description 12
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 238000010352 biotechnological method Methods 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 238000010189 synthetic method Methods 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 230000009266 disease activity Effects 0.000 description 13
- 208000017169 kidney disease Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 238000010219 correlation analysis Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 108010053770 Deoxyribonucleases Proteins 0.000 description 4
- 102000016911 Deoxyribonucleases Human genes 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 238000013357 binding ELISA Methods 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000005777 Lupus Nephritis Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 108010058684 R18 peptide Proteins 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Chemical class 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical class [H]OC(*)=O 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000000585 glomerular basement membrane Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000005499 meniscus Effects 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- MWOGMBZGFFZBMK-LJZWMIMPSA-N (2s)-2-[[(2s)-2-[[2-[[(2s,3s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MWOGMBZGFFZBMK-LJZWMIMPSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010058556 Serositis Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000009433 disease-worsening effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- -1 ferric Chemical class 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011862 kidney biopsy Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000002988 nephrogenic effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 108010052768 tyrosyl-isoleucyl-glycyl-seryl-arginine Proteins 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 哺乳類患者の全身性紅斑性狼瘡を治療する方法であって、少なくとも一 つのラミニンペプチド、又はその類縁体若しくは誘導体を前記患者に有効量投与 することを具備する方法。 2. 請求項1に記載の方法であって、前記少なくとも一つのラミニンペプチ ドが、R38並びに5200、5104、5105、5106、5107、5108、5109、及び5110を含む それらのR38類縁体及びそれらの誘導体からなる群から選択される方法。 3.全身性紅斑性狼瘡に罹患している哺乳類患者への投与に適する医薬を製造 するための少なくとも一つのラミニンペプチドの使用。 4.請求項3に記載の使用であって、前記少なくとも一つのラミニンペプチド が、R38並びに5200、5104、5105、5106、5107、5108、5109、及び5110を含むR38 類縁体及びそれらの誘導体からなる群から選択される使用。 5.有効量の少なくとも一つのラミニン由来ペプチド及び薬学的に許容される 担体を含有する全身性紅斑性狼瘡を治療するための薬学的組成物。 6.請求項5に記載の薬学的組成物であって、前記少なくとも一つのラミニン ペプチドが、R38並びに5200、5104、5105、5106、5107、5108、5109、及び5110 を含むR38類縁体及びそれらの誘導体からなる群から選択される薬学的組成物。 7.全身性紅斑性狼瘡の活性をモニタリングする方法であって、 (a)患者から尿のサンプルを得るステップと、 (b)R38抗原と特異的に結合する、前記サンプル中のR38結合抗体を検出する ステップと、 (c)前記R38結合抗体の量を対照値と比較するステップと、 を具備する方法。 8.請求項7に記載の方法であって、前記対照値が前記患者から得た従前の結 果である方法。 9.患者のSLEの進行をモニタリングする方法であって、 (a)前記患者から得た尿サンプルを、固相に結合されたR38ペプチド又はその 断片とインキュベートするステップと、 (b)R38抗原と特異的に結合する、前記サンプル中のR38抗体を検出すること と、 (c)結合したR38ペプチドの量を対照値と比較するステップと を具備する方法。 10.請求項7〜9に記載の方法であって、前記抗原が直接的又は間接的に固 相物質上に固定化されている方法。 11.アミノ酸配列 を有する群から選択されるペプチド。 からなる群から選択されるアミノ酸配列を有するペプチドをコードする核酸配列 。 13.前記核酸が、DNA、RNA、cDNA、ゲノムDNA、合成DNA、mRNA、全RNA、及 びhnRNAからなる群から選択される請求項12に記載の核酸配列。 14.ラミニンペプチド又はそれらの類縁体若しくは誘導体に対して誘導され た単一特異性抗体。 15.前記ラミニンペプチド、類縁体、又はそれらの誘導体が、R38並びに520 0、5104、5105、5106、5107、5108、5109、及び5110を含むR38類縁体及び誘導体 からなる群から選択される請求項14の単一特異性抗体。 16.ラミニンペプチド又はその類縁体若しくは誘導体に対して誘導されたポ リクローナル抗体。 17.請求項16のポリクローナル抗体であって、前記ラミニンペプチド、そ れらの類縁体又は誘導体が、R38並びに5200、5104、5105、5106、5107、5108、5 109、及び5110を含むR38類縁体及びそれらの誘導体からなる群から選択され るポリクローナル抗体。 18.ラミニンペプチド又はそれらの類縁体若しくは誘導体に対して誘導され たモノクローナル抗体。 19.請求項18のモノクローナル抗体であって、前記ラミニンペプチド、そ れらの類縁体又は誘導体が、R38並びに5200、5104、5105、5106、5107、5108、5 109、及び5110を含むR38類縁体及びそれらの誘導体からなる群から選択されるモ ノクローナル抗体。 20.R38とC72抗DNA抗体への結合を競合するときに、85μg/mLを超えない用 量で、50%結合阻害活性を有するラミニン由来ペプチドをコードする核酸。 21.ELISAによる一時間後の吸光度が少なくとも0.75と測定される、C72マウ ス抗DNA抗体との直接結合活性を有するラミニン誘導ペプチドをコードする核酸 。 22.ELISAによる二時間後の吸光度が少なくとも1と測定される、B3ヒト抗D NA抗体との直接結合活性を有するラミニン誘導ペプチドをコードする核酸。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL120503 | 1997-03-20 | ||
IL12050397A IL120503A0 (en) | 1997-03-20 | 1997-03-20 | Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them |
PCT/IB1998/000415 WO1998042737A2 (en) | 1997-03-20 | 1998-03-20 | Peptides for the treatment of systemic lupus erythematosus |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001524826A true JP2001524826A (ja) | 2001-12-04 |
JP4459307B2 JP4459307B2 (ja) | 2010-04-28 |
Family
ID=11069947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54532898A Expired - Fee Related JP4459307B2 (ja) | 1997-03-20 | 1998-03-20 | 全身性紅斑性狼瘡を治療するためのペプチド |
Country Status (13)
Country | Link |
---|---|
US (1) | US6228363B1 (ja) |
EP (1) | EP0972032B1 (ja) |
JP (1) | JP4459307B2 (ja) |
AT (1) | ATE348885T1 (ja) |
AU (1) | AU734444B2 (ja) |
CA (1) | CA2283792A1 (ja) |
DE (1) | DE69836679T2 (ja) |
DK (1) | DK0972032T3 (ja) |
ES (1) | ES2279567T3 (ja) |
IL (2) | IL120503A0 (ja) |
NZ (1) | NZ337953A (ja) |
PT (1) | PT972032E (ja) |
WO (1) | WO1998042737A2 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7129052B1 (en) | 2000-07-12 | 2006-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Peptides and their utility in modulation of behavior of cells expressing α3β1 integrins |
WO2001005812A2 (en) * | 1999-07-15 | 2001-01-25 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | PEPTIDES AND THEIR UTILITY IN MODULATION OF BEHAVIOR OF CELLS EXPRESSING α3β1 INTEGRINS |
US20020031788A1 (en) * | 2000-02-18 | 2002-03-14 | Rosenberg E. William | Characterization of microbial deposition and immune response at the basement membrane and methods relating thereto |
IL141647A0 (en) * | 2001-02-26 | 2002-03-10 | Yeda Res & Dev | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
EA008438B1 (ru) * | 2003-01-14 | 2007-06-29 | Тева Фармасьютикал Индастриз, Лтд. | Парентеральные композиции пептида для лечения системной красной волчанки |
EA009123B1 (ru) * | 2003-01-14 | 2007-10-26 | Тева Фармасьютикал Индастриз, Лтд. | Парентеральные композиции пептидов для лечения системной красной волчанки |
CA2605321A1 (en) | 2005-04-19 | 2006-10-26 | Eli Lilly And Company | Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease |
US20100285146A1 (en) * | 2007-05-24 | 2010-11-11 | Yaakov Naparstek | Peptides and methods for the treatment of systemic lupus erythematosus |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5266328A (en) * | 1990-08-27 | 1993-11-30 | Regents Of The University Of Minnesota | Laminin a chain polypeptides from the carboxy terminal globular domain |
JPH06504271A (ja) | 1990-09-14 | 1994-05-19 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | 免疫グロブリンの構造に基づく生物活性なペプチドのデザイン |
US6013628A (en) * | 1994-02-28 | 2000-01-11 | Regents Of The University Of Minnesota | Method for treating conditions of the eye using polypeptides |
IL108811A (en) * | 1994-03-01 | 1998-06-15 | Hadasit Med Res Service | Immunoassay reagents, kits and methods |
US5493008A (en) * | 1994-08-15 | 1996-02-20 | The University Of Virginia Patent Foundation | Two non-contiguous regions contribute to nidogen binding to a single EGF-like motif of the laminin γ1 chain |
EP0765660A3 (en) * | 1995-09-28 | 1998-09-23 | Takeda Chemical Industries, Ltd. | Microcapsules comprising 2-piperazinone-1-acetic acid compounds |
-
1997
- 1997-03-20 IL IL12050397A patent/IL120503A0/xx unknown
-
1998
- 1998-03-20 JP JP54532898A patent/JP4459307B2/ja not_active Expired - Fee Related
- 1998-03-20 PT PT98907114T patent/PT972032E/pt unknown
- 1998-03-20 DE DE69836679T patent/DE69836679T2/de not_active Expired - Lifetime
- 1998-03-20 EP EP98907114A patent/EP0972032B1/en not_active Expired - Lifetime
- 1998-03-20 CA CA002283792A patent/CA2283792A1/en not_active Abandoned
- 1998-03-20 ES ES98907114T patent/ES2279567T3/es not_active Expired - Lifetime
- 1998-03-20 WO PCT/IB1998/000415 patent/WO1998042737A2/en active IP Right Grant
- 1998-03-20 AU AU63065/98A patent/AU734444B2/en not_active Ceased
- 1998-03-20 NZ NZ337953A patent/NZ337953A/en unknown
- 1998-03-20 AT AT98907114T patent/ATE348885T1/de not_active IP Right Cessation
- 1998-03-20 DK DK98907114T patent/DK0972032T3/da active
-
1999
- 1999-09-16 IL IL131950A patent/IL131950A/en not_active IP Right Cessation
- 1999-09-20 US US09/399,494 patent/US6228363B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO1998042737A3 (en) | 1998-11-05 |
DK0972032T3 (da) | 2007-04-10 |
CA2283792A1 (en) | 1998-10-01 |
DE69836679T2 (de) | 2007-10-04 |
AU734444B2 (en) | 2001-06-14 |
IL120503A0 (en) | 1997-07-13 |
NZ337953A (en) | 2002-03-28 |
PT972032E (pt) | 2007-03-30 |
ATE348885T1 (de) | 2007-01-15 |
JP4459307B2 (ja) | 2010-04-28 |
AU6306598A (en) | 1998-10-20 |
DE69836679D1 (de) | 2007-02-01 |
IL131950A (en) | 2006-07-05 |
US6228363B1 (en) | 2001-05-08 |
EP0972032A2 (en) | 2000-01-19 |
WO1998042737A2 (en) | 1998-10-01 |
ES2279567T3 (es) | 2007-08-16 |
EP0972032B1 (en) | 2006-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100418984C (zh) | N-11端截短的β-淀粉样蛋白的单克隆抗体、组合物、方法和用途 | |
WO1991016628A1 (en) | Purification, detection and methods of use of protease nexin-2 | |
AU2006263942B2 (en) | Method for diagnosing rheumatic diseases | |
Zuo et al. | Long-term active immunization with a synthetic peptide corresponding to the second extracellular loop of β1-adrenoceptor induces both morphological and functional cardiomyopathic changes in rats | |
US20090068102A1 (en) | Treating stroke | |
JP2010202653A (ja) | 抗梗塞分子 | |
JP4459307B2 (ja) | 全身性紅斑性狼瘡を治療するためのペプチド | |
JPH02479A (ja) | snRNP−A抗原及びそのフラグメント | |
WO2007049424A1 (ja) | 肝線維化抑制剤 | |
US20080213270A1 (en) | Neurotensin as a marker and therapeutic target for sepsis | |
US5367063A (en) | Human phospholipase activating protein and methods for diagnosis of rheumatoid arthritis | |
Cohen | Proteins of the systemic amyloidoses | |
JP4065322B2 (ja) | 合成ペプチドおよびそれらを含有する医薬組成物 | |
US20020054872A1 (en) | Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus | |
WO1995013291A1 (en) | Neuron-glia cell adhesion molecule, ng-cam, in treatment of nerve damage | |
Busch | A view of type I and II Na+/P (i) transporters through microelectrodes. | |
EP1089794A2 (en) | Methods for inhibiting tef-3 activity | |
AU1217099A (en) | Neuron-glia cell adhesion molecule, NG-CAM, in treatment of nerve damage | |
JP2003279567A (ja) | スクリーニング方法 | |
TW201134484A (en) | Therapeutic use | |
WO2004050007A2 (en) | Mammalian bt-42 proteins involved in the regulation of energy homeostasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050214 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070731 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071031 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071129 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080610 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080904 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090511 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100112 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100210 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130219 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |